参芪和胃散治疗慢性非萎缩性胃炎临床研究  

A study on treating chronic non-atrophic gastritis with Shenqi Hewei San

作　　者：郑毅 

机构地区：[1]江苏省新沂市中医院,江苏新沂221400

出　　处：《中医临床研究》2018年第22期87-88,共2页Clinical Journal Of Chinese Medicine

摘　　要：目的:研究慢性非萎缩性胃炎患者采用参芪和胃散治疗的临床效果。方法:选取2014年7月-2016年12月在我院就诊的82例慢性非萎缩性胃炎患者,采用随机抽签法分为治疗组(42例,参芪和胃散口服治疗)和对照组(40例,采用质子泵抑制剂、胃黏膜保护剂、胃肠动力药等常规治疗),对比两组患者治疗效果、临床症状积分、不良反应以及复发率等情况。结果:治疗组患者治疗总有效率(97.6%)显著高于对照组(82.5%),治疗组患者治疗后胃脘痞胀、胃脘疼痛、食欲不振等临床症状积分均明显低于对照组(P<0.05),治疗组患者未发现不良反应,对照组2例出现不良反应,不良反应发生率为5.0%。经1年时间随访,治疗组1例患者复发,对照组4例患者复发,治疗组患者复发率(2.4%)显著低于对照组(10.0%)。结论:参芪和胃散治疗慢性非萎缩性胃炎的临床疗效较为显著,能显著改善患者胃炎的不适症状,且副作用少,对改善患者预后治疗,减少复发率效果明显,值得临床推广。Objective:To study the clinical effects of Shenqi Hewei San(参芪和胃散)on chronic non-atrophic gastritis.Methods:82 patients were randomly divided into the treatment group(42 cases were treated with Shenqi Hewei San)and control group(40 cases were given routine treatment,such as proton pump inhibitors,gastric mucosal protective agents and gastrointestinal motility drugs).The treatment effects,clinical symptom scores,adverse reactions and recurrence rates in two groups were compared.Results:The total efficiency was 97.6%in the treatment group,and significantly higher than 82.5%in the control group.The symptom scores(such as stomach swelling,epigastric pain and loss of appetite)after treatment in the treatment group were significantly lower than in the control group(P<0.05).No adverse reactions were observed in the treatment group.The incidence of adverse reactions was 5.0%in the control group.After 1 year of follow-up,the recurrence rate in the treatment group was 2.4%,and significantly lower than 10.0%in the control group.Conclusion:Shenqi Hewei San shows a significant effect on chronic non-atrophic gastritis.It can significantly improve the discomfort of patients with gastritis and has fewer side effects,can improve the prognosis,reduce the recurrence rate,and is worthy of clinical promotion.

关 键 词：慢性非萎缩性胃炎 参芪和胃散 临床研究 

分 类 号：R573.3[医药卫生—消化系统]